CureVac(CVAC) - 2022 Q4 - Annual Report

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update · In 2022, ongoing business transformation driven by COVID-19 and flu clinical developments in collaboration with GSK and successful broadening of oncology footprint o Monovalent modified COVID-19 candidate CV0501 demonstrated efficient booster activity and good tolerability across now available dose range of 3 to 200µg o Modified mRNA technology selected as preferred technology; on track with new clin ...